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Focal segmental glomerulosclerosis (FSGS) is one of the primary glomerular disorders in both children and adults which can
progress to end-stage renal failure. Although there are genetic and secondary causes, circulating factors have also been regarded
as an important factor in the pathogenesis of FSGS, because about 40% of the patients with FSGS have recurrence after renal
transplantation. Soluble urokinase-type plasminogen activator receptor (suPAR) is a soluble form of uPAR, which is a membrane-
bound protein linked to GPI in various immunologically active cells, including podocytes. It has recently been suggested as a
potential circulating factor in FSGS by in vitro podocyte experiments, in vivo mice models, and human studies. However, there
have also been controversies on this issue, because subsequent studies showed conflicting results. suPAR levels were also increased
in patients with other glomerular diseases and were inversely correlated with estimated glomerular filtration rate. Nevertheless,
there has been no balanced review on this issue. In this review, we compare the conflicting data on the involvement of suPAR
in the pathogenesis of FSGS and shed light on interpretation by taking into account many points and the potential variables and
confounders influencing serum suPAR levels.
1. Background
Focal segmental glomerulosclerosis (FSGS) is a primary
glomerular disorder with 50% of patients progressing to end-
stage renal disease (ESRD) in those unresponsive to treat-
ment [1–3]. FSGS can be divided into primary and secondary
forms, but overlap of clinical and histologic features hampers
differentiation in some cases [2]. It is considered to be a lesion
with diverse clinical features and different pathophysiologic
mechanisms and response to treatment [1–3].
Recent evidence shows that FSGS is mainly a “podocy-
topathy” with several podocyte-related molecules implicated
in development and course of the disease, which is supported
by insights into genetics from hereditary forms [4–6]. Circu-
lating factors may be directly implicated in the pathogenesis
of FSGS, since about 40% of the patients with primary FSGS
have recurrence after kidney transplantation (KT), which
may be higher in children than in adults, and significant
progress of their pivotal role in the pathogenesis of primary
FSGS has been achieved recently [7, 8].
Soluble urokinase-type plasminogen activator receptor
(suPAR) has recently been suggested as a potential circulating
factor in FSGS [9–13]. However, there have also been contro-
versies on this issue, because suPAR levels were also increased
in those with other glomerular diseases and were inversely
correlated with estimated glomerular filtration rate (GFR)
[14–24].
To resolve these discrepancies, we discuss current knowl-
edge regarding the role of suPAR in the pathogenesis of pri-
mary FSGS and compare the conflicting data on this issue by
taking into account the potential variables influencing serum
suPAR levels with a balanced review.
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2. The Role of Circulating Permeability
Factors in FSGS
A role of a circulating factor in the etiopathogenesis of FSGS
has first been proposed in 1972, when Hoyer and colleagues
described a case series of patients with recurrent FSGS after
KT [25]. Risk factors for disease recurrence include younger
age, heavy proteinuria, higher baseline creatinine at the onset
of the disease, and rapid progression to ESRD [26, 27]. Biop-
sies obtained from patients with recurrent FSGS resemble
the same histologic subtype in a majority of patients. Plasma-
pheresis can remove the circulating factor and achieve remis-
sion in a subset of children and adults with FSGS [26, 28].
The putative circulating factor of patients with recurrent
FSGS appeared to be bound to protein A and hydrophobic-
interaction columns [29] and further investigations suggested
the molecular mass of this factor to be around 30–50 kDa.
Injection of supernatant from FSGS sera revealed threefold
increased proteinuria in rats after 6 to 24 hours [30].
Onset of proteinuria after exposure to the circulatory
factor could be influenced by several components, that is,
apolipoproteins which might prevent glomerular albumin
permeability after incubation with FSGS sera [31]. Undefined
components of normal sera could prevent the increase of
glomerular albumin permeability in cultured rat glomeruli
[32]. Likewise, application of galactose might diminish glom-
erular albumin permeability in recurrent FSGS, indicating
high affinity of the circulating factor for galactose [33, 34].
Transmission of the glomerular permeability factor
from a mother to her unborn child further highlights the
pathogenic role of a circulating permeability factor [35].
There have been several factors which have been proposed
as potential candidates in the pathogenesis of primary FSGS
such as vasodilator stimulated phosphoprotein (VASP) [36]
or cardiotrophin-like-cytokine-1 (CLC-1) [7, 37]. Although
not proved in FSGS, protein tyrosine phosphatase receptor-
O (PTPRO) was suggested to increase glomerular albumin
permeability [7, 37]. suPAR has recently been suggested as a
potential circulating factor in FSGS by Wei et al. [9].
3. uPAR and suPAR
The urokinase-type plasminogen activator (uPA) system is
composed of a protease, a receptor (uPAR), and inhibitors
[38]. uPARwas cloned in 1990 [39] and is amembrane-bound
45–55 kDa protein with three domains (DI, DII, and DIII)
linked to glycosylphosphatidylinositol (GPI) [38]. It is present
in various immunologically active cells, such as neutrophils,
lymphocytes, monocytes, macrophages, activated T cells,
endothelial cells,megakaryocytes, tumor cells, and podocytes
(Figure 1) [9, 38, 40–43]. uPAR can bind to various ligands
such as uPA, vitronectin, and integrins [44]. Upon binding
of uPA to its receptor (uPAR) it mediates various cellular
activities such as adhesion, migration, differentiation, and
proliferation [38]. In podocytes, uPAR is one of the pathways
capable of activating 𝛼v𝛽
3
integrin promoting cell motility
and activation of small GTPases, such as Cdc42 and Rac1,
which can lead to podocyte contraction, shifting from a
stationary to motile phenotype and leading to foot process
effacement and proteinuria (Figure 1) [45].
If uPAR is cleaved from the cell surface, a soluble form
of uPAR (suPAR) is released [38, 46]. Full-length suPAR
(suPARI–III) can be cleaved into another two soluble forms
with different biologic properties, suPARII-III and suPARI
[38]. The I–III portion of suPAR can compete with uPARI–III
for uPA binding [47]. suPAR can be found in various body
fluids including blood, plasma, serum, urine, saliva, and cere-
brospinal fluid (CSF) in different concentrations [22, 48, 49]
and have similar functions as uPAR [38].
suPAR can be measured with a monoclonal anti-
body double sandwich enzyme-linked immunosorbent assay
(ELISA)method using commercially available kits (e.g., R&D
Systems, Minneapolis, MN, USA; suPARnostic, Virogates,
Copenhagen, Denmark), but only R&D Systems were used in
all the suPAR studies in FSGS. In healthy individuals, suPAR
levels are stable in blood and urine and the whole molecule of
suPAR was documented in serum and two truncated soluble
forms of the entire molecule (suPARI and suPARII-III) in
the urine [50]. Elevated plasma or serum suPAR levels have
been demonstrated in patients with various diseases, such
as cancer, sepsis, systemic inflammatory response syndrome,
and cardiovascular disease [51–55] and have been shown to be
associated with a poor clinical outcome. The fact that suPAR
is elevated by a large number of diseases, in particular liver
and kidney diseases, makes it unlikely that suPAR can ever be
used as a diagnostic biomarker (for FSGS or other diseases).
In summary, uPAR is a membrane-bound protein linked
to GPI in various immunologically active cells, including
podocytes, and is released as suPAR.
4. The Role of uPAR Signaling and
Integrin Activation in Podocytes and
Proteinuric Kidney Diseases
Podocyte foot processes contain an actin cytoskeleton, which
is connected to the glomerular basement membrane by 𝛼3𝛽
1
and 𝛼v𝛽
3
integrin as well as 𝛼 and 𝛽-dystroglycans [56].
Induction of uPAR signaling in podocytes leads to foot pro-
cess effacement and urinary protein loss by lipid-dependent
activation of 𝛼v𝛽
3
integrin [45]. Conversely, blocking of
𝛼v𝛽
3
integrin also reduced podocyte motility in vitro and
lowered proteinuria in mice [45]. Also, mice lacking uPAR
(plasminogen activator, urokinase receptor, PLAUR−/−) were
protected from lipopolysaccharide- (LPS-)mediated protein-
uria but developed disease after expression of a constitutively
active 𝛼v𝛽
3
integrin, suggesting the pathogenic role of uPAR
signaling in the pathogenesis of proteinuric kidney diseases
including FSGS [9, 45].
Recently, other groups provide further supportive evi-
dence [57–62]. Inducible podocyte-specific expression of
constitutively active nuclear factor of activated T cells
(NFATc1) increased podocyte uPAR expression by binding to
the PLAUR gene promoter [57]. Pathological uPAR signals in
podocytes were independent of T cells and affected cell
motility via activation of 𝛽
3
integrin. This could be blocked
by cyclosporine, NFAT-siRNA, or NFAT inhibitor in ani-
mal models of glomerular diseases such as LPS-treated or
5/6 nephrectomized rats [57]. Rapamycin could promote
Journal of Immunology Research 3
Rituximab
Endothelial cells
SMPDL-3b
ASMase
and
Another 
soluble 
factor
Cell membrane
uPAR (CD87)
Cytokines 
suPAR
uPAR
Foot
process
Cyclosporine CalcineurinNFAT
GTP-Rac1
Lamellipodia
GTP-Cdc42
Filopodia
Motile phenotype
Foot process effacement
Proteinuria
NK cell T cellNeutrophil
DIDIII
DII
DIDIII
DII
antagonist
suPAR
MMF
Vitamin D
Amiloride
V Vinculin
V
Podocyte
GBM
Dispersion
TNF-𝛼Anti-TNF-𝛼
(e.g., TNF-𝛼)
𝛼
𝛼-a
ct-
4
v
𝛼
v 𝛼v
GPI anchor
cleavage
𝛽3
𝛽3
𝛽3 integrin
Figure 1: A hypothesis for the pathogenesis of suPAR-mediated FSGS. suPAR is formed from various immune cells after cleavage of GPI
anchor by cytokines such as TNF-𝛼. suPAR can activate 𝛼v𝛽
3
integrin of podocytes. TNF-𝛼 can directly activate podocyte 𝛼v𝛽
3
integrin
and vinculin. Another serum factors might decrease SMPDL3b in podocytes, causing 𝛼v𝛽
3
integrin activation through increased binding
of suPAR/uPAR and 𝛼v𝛽
3
integrin. Cdc42 and Rac1 can be activated by uPAR-𝛼v𝛽
3
integrin signaling and the podocyte actin cytoskeleton
shifts from a stationary to a motile phenotype, thereby causing foot process effacement and proteinuria. uPAR-𝛼v𝛽
3
integrin signaling in
podocytes can be blocked through various pathways. NK, natural killer; uPAR, urokinase-type plasminogen activator receptor; suPAR,
soluble urokinase-type plasminogen activator receptor; GPI, glycosylphosphatidylinositol; TNF, tumor necrosis factor; NFAT, nuclear factor
of activated T cells; MMF, mycophenolate mofetil; GTP, guanosine-5󸀠-triphosphate; SMPDL, sphingomyelin phosphodiesterase acid-like;
ASMase, acid sphingomyelinase.
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podocyte migration through the upregulation of uPAR, pro-
viding a new mechanism of rapamycin-associated protein-
uria [58]. Conversely, several drugs targeting podocyte uPAR
expression, such as vitamin D, amiloride, or mycophenolate
mofetil (MMF), have recently been shown to be effective in
reducing proteinuria in various experimental models, such
as FSGS or lupus mice [59–61]. Recently, it was reported that
rituximab might also inhibit uPAR-𝛽
3
integrin signaling via
modulation of sphingomyelin phosphodiesterase acid-like 3b
(SMPDL-3b) [62]. These cellular events are well summarized
in Figure 1. In addition to uPAR-integrin signaling, podocyte
vascular endothelial growth factor (VEGF)-A regulates 𝛼v𝛽
3
integrin signaling in the glomerulus, and podocyte VEGF
knockdown disrupts 𝛼v𝛽
3
integrin activity [63].
In summary, uPAR-𝛼v𝛽
3
integrin signaling is an impor-
tant pathway in the pathogenesis of proteinuria in various
kidney diseases.
5. The Role of suPAR in Podocytes and FSGS
Wei et al. reported that circulating suPAR could activate 𝛽
3
integrin in a similar manner to membrane-bound uPAR in
podocytes by using themethods of coimmunoprecipitation of
suPARand𝛽
3
integrin and the activating epitope-recognizing
antibodies such as the 𝛽
3
integrin-specific antibody AP5 [9].
They found that the incubation of podocytes with recombi-
nant suPAR strongly induces AP5 signal in a specific pattern
highlighting areas of focal adhesions, which are known to
be the location of 𝛽
3
integrin. This effect was blocked by a
blocking specific uPAR antibody [9].
They established three different mouse models [9]. The
first was PLAUR−/− mice: high-dose recombinant mouse
suPARI–III induced proteinuria and foot process effacement,
prominent deposits of suPAR on podocytes as well as
increased podocyte𝛽
3
integrin activity [9].The secondmodel
was hybrid-transplant mice modeling endogenous suPAR
release in which a kidney from PLAUR−/− mice was trans-
planted in a wild-typemouse and proteinuria developed after
LPS-induced suPAR production, indicating that circulating
suPAR may be able to activate 𝛽
3
integrin independently of
uPAR [9]. The third model was genetically engineered wild-
type mice. Wild-type mice were injected with a suPARI-II-
producing plasmid into their skin, which caused increased
serum suPAR concentrations and FSGS-like lesions with pro-
teinuria. A plasmid with a point mutation in the DII domain
induced synthesis of suPAR in wild-type mice. However,
this was unable to bind to 𝛽
3
integrin and did not induce
proteinuria [9].
In their study, serum suPAR concentrations were signifi-
cantly elevated in patients with FSGS compared to those with
minimal change disease (MCD, either in relapse or remis-
sion), membranous nephropathy (MN), preeclampsia, and
healthy subjects [9]. suPAR concentrations correlated with
the activity of podocyte 𝛽
3
integrin and inhibition of suPAR
by cycloRGDfV or antibodies specific against uPAR and
plasmapheresis could lower AP5 activity on podocytes [9].
They also found a predominant suPAR fragment at ∼22 kDa
and the other two forms at ∼45 and 40 kDa, albeit at much
lower expression levels [9]. However, serum uPA concen-
trations did not differ between FSGS and other glomerular
diseases [9].
In summary, Wei et al. [9] reported an important role of
suPAR in the pathogenesis of FSGS with in vitro podocytes,
3 mice models of FSGS, and FSGS patients.
6. Subsequent Clinical Observations
Supporting the Pathogenic Role of
suPAR in FSGS
In two large cohorts, circulating suPAR levels were elevated in
84.3% (North American) and 55.3% (the European PodoNet)
of the FSGS patients compared with 6% of controls [10].
Inflammation did not account for this difference [10]. Serum
suPAR levels were also increased in FSGS compared to other
glomerulopathies such as MCD or MN and healthy subjects
[9–13]. However, serum suPAR levels did not differ between
primary and secondary FSGS [12]. One study showed that
elevated suPAR levels in primary FSGS were not merely
attributable to decreased estimated eGFR, because suPAR
levels of primary FSGS were still significantly higher than
MCDorMNafter adjusting for renal function [12]. One study
reported the usefulness of suPARmeasurements in predicting
steroid response in patients with primary FSGS [13].
In 2001, Kemper et al. reported an infant with transient
proteinuria born to a mother with FSGS [35] and a recent
reanalysis of stored samples revealed highly elevated suPAR
levels in both the mother and the newborn [64]. Extracorpo-
real treatment reduced suPAR, podocyte 𝛽
3
integrin activa-
tion, podocyte effacement, and proteinuria in recurrent FSGS
patients in accordance with reduction of suPAR levels [65,
66].
Recently, it was reported that urinary suPAR levels of
patients with primary FSGS were significantly higher com-
pared to those with MCD, MN, and secondary FSGS and
normal subjects [67] and positively correlated with 24-hour
urinary protein excretion in primary FSGS. During follow-
up, urinary suPAR levels decreased in patients with complete
remission. After incubation of human podocytes with urine
obtained from patients with primary FSGS, the AP5 signal
was induced and it could be reduced by a blocking antibody
to uPAR [67].
7. Clinical Observations Not Supporting the
Pathogenic Role of suPAR in FSGS
Although increased suPAR levels resulted in FSGS-like
glomerular lesions and proteinuria inPLAUR−/−mice [9], the
pathogenic effects of suPAR were not observed in wild-type
mice, in which proteinuria or podocyte foot process efface-
ment did not occur despite glomerular suPAR deposition [23,
68]. suPAR concentrations did not distinguish patients with
FSGS from other glomerular histopathologies such as MCD,
MN, IgA nephropathy, and lupus nephritis or nonglomerular
chronic kidney disease (CKD), suggesting that suPAR might
be involved in the pathogenesis of various renal diseases
as a nonspecific marker or impaired glomerular integrity
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might affect its clearance [14–24]. Moreover, eGFR was
the strongest determinant of suPAR concentration [14–24].
Therefore,morework is warranted and justified to explore the
role of suPAR in FSGS and other glomerular diseases.
Wei et al. reported that pretransplant serum suPAR levels
predicted posttransplant recurrence of FSGS [9], whereas
several other investigators found no evidence that serum
suPARwas a specific marker for FSGS recurrence [18, 22, 69].
Although there have been studies demonstrating a decrease of
suPAR after the induction of remission [10, 12, 65, 66], others
demonstrated similar serum levels regardless of therapeutic
response [15, 18, 70]. Recently, it was demonstrated that
urinary suPAR levels rather than serum suPAR levels might
be helpful in the early identification of patients at high risk of
posttransplant FSGS recurrence [22].
Froman epidemiologic point of view, statistical validation
is also one of the important steps to be a reliable surrogate
biomarker from biomarker discovery to clinical utility [71]. A
biomarker for clinical use needs good sensitivity and speci-
ficity (e.g., ≥0.9) and good positive and negative predictive
value. However, previous studies on suPAR had many prob-
lems in the study designs, sample collection, and statistical
analysis techniques. Most studies on suPAR were conducted
in a retrospective design and the selection of healthy controls
was not matched for age, sex, and other parameters influenc-
ing suPAR levels. With regard to statistics, most studies did
not perform multiple logistic regression analysis to find an
independent predictor and receiver operating characteristics
(ROC) curve analysis to calculate sensitivity and specificity,
an essential prerequisite to be a biomarker, but simply
presented the differences of suPAR levels among groups.
Furthermore, some studies did not present the mean ± stan-
dard deviation (SD), hampering the meta-analysis of several
suPAR studies. If there are many factors influencing suPAR
levels, an individual patient data meta-analysis and propen-
sity score matching would be important statistical methods
to elucidate whether suPAR could be a reliable surrogate
biomarker in this field.
There has also been interest in reproducibility concerns in
medicine [72]. In addition to registration of the study design
(i.e., http://www.clinicaltrials.gov/), the adoption and follow-
ing of the guidelines such as STrengthening the Reporting of
OBservational studies in Epidemiology (STROBE) for cohort
and case control studies would increase the reproducibility
and reliability in human studies [73]. Irreproducibility of
preclinical animal data can also lead to the failure of human
clinical trials and ARRIVE (Animal Research: Reporting of
In Vivo Experiments) for animal studies which may improve
the quality of animal research and increase transparency and
reproducibility [74].
8. Areas of Uncertainty concerning Preclinical
Studies Investigating suPAR in FSGS
8.1. Different Mice Models Used in suPAR Studies. The search
for a good model of human recurrent FSGS is indeed a key
to future studies and has yet to be developed. In our opinion,
themost appropriatemousemodel to study FSGS-like lesions
should be determined. The animal models described are
specific to studies of suPAR and may not be useful if other
factors or cofactors are responsible for this disease.WhileWei
et al. used PLAUR−/− mice and genetically engineered wild-
type mice with injection of a suPARI-II-producing plasmid,
most others performed studies with wild-type mice [9].
Maas et al. pointed out that wild-type nonproteinuric mice
used in the original study already exhibited suPAR levels
of approximately 3,000 pg/mL at baseline before activation
of the plasmid [75]. After initiation of recombinant suPAR
expression, mice developed proteinuria along with a sharp
rise in urinary suPAR excretion and rise of serum suPAR.
However, these mice with high baseline suPAR might be
prone to develop FSGS [9]. In contrast, Cathelin et al. used
wild-type C57BL/6J and 129S2/SvPas mice and intravenous
administration of suPAR could not cause proteinuria despite
massive suPAR deposits in the glomeruli in these mice and
did not aggravate proteinuria in LPS-treated C57BL/6J mice
[68]. They addressed that if the genetic ablation of PLAUR in
the kidney is the cause of the effect observed on proteinuria,
it is difficult to translate this finding to the pathogenesis of
FSGS in humans.They also pointed out that the plasmid used
in genetically engineeredWTmice byWei et al. [9] encodes a
truncated mRNA splice variant of mouse uPAR covering the
first 133 residues of the full-length receptor and this particular
splice mRNA transcript may not be translated into a folded
protein product in vivo because it encodes only one and one
half LU-domain [68].
Spinale et al. also used wild-type and a transgenic mouse
model continuously inducing hepatic suPAR expression
(D1D2D3) in which proteinuria did not develop despite an
increase of suPAR [23]. They pointed out that Wei et al.
[9] injected a commercially available mouse recombinant
Fc-fusion protein in short-term experiments that coupled
a human IgG1 Fc-domain to mouse uPAR lacking a GPI-
linkagemotif and it has not been determinedwhether IgG1 Fc
domain containing protein engendered complement fixation-
dependent glomerular injury [23]. They also addressed that
Wei et al. [9] used a mouse suPAR cDNA fragment obtained
from a purchased cDNA clone (IMAGE cDNAclone 3158012)
containing a retained intron 4 (uPAR-intron 4) and the
mouse splice variant encoding uPAR-intron 4 is rare and the
expression of the protein associated with this variant has not
been reported [23]. In addition, they indicated that Wei et al.
[9] reported the creation of a control mouse suPAR construct
with an E134A mutation intended to abrogate binding of
mouse suPAR to 𝛽
3
integrin, but a similar 𝛽
3
integrin binding
motif has not been described in mouse uPAR [23].
In various inflammatory conditions, an increase in serum
suPAR levels has been reportedwhichwas not associatedwith
proteinuria [38, 48, 53, 54, 76], suggesting that suPAR itself
may not be sufficient to induce nephrotic proteinuria as in
wild-type mice.
In our opinion, however, the threshold of serum suPAR at
which proteinuria and a FSGS-like lesion develop should be
determined both in wild-type mice [23, 68] and in PLAUR−/−
mice [9], requiring further dose-response experiments in
different animal models of FSGS in the future. We speculate
that much higher doses and more prolonged administration
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of suPAR could be used to determine the threshold in wild-
type mice. In addition, with regard to the measurements of
suPAR levels in mice, Cathelin et al. did not measure serum
suPAR levels in suPAR-treated mice [68]. Wei et al. described
that murine suPAR was evaluated by an in-house ELISA kit
[9] and Spinale et al. reported that suPAR concentration in
mouse serum was measured with a kit from R&D Systems
(Minneapolis, MN) (DY531) which has been validated by the
manufacturer for detection of mouse suPAR in cell super-
natant [23]. The measurements of suPAR levels by ELISA
methods in mice should be unified and further validated
in both wild-type and genetically engineered mice in future
studies for the comparison.
In summary, we cannot say that suPAR is not involved in
the pathogenesis of FSGS in mice, because different experi-
mental models were used.
8.2. In Vitro suPAR Studies on Podocytes. Wei et al. demon-
strated that recombinant suPAR activates 𝛽
3
integrin (AP5
staining) in a similar manner to membrane-bound uPAR
in podocytes, which was blocked by an antibody specific
to uPAR. Currently, however, no further study has repeated
and validated these findings [9]. Therefore, factors mediat-
ing suPAR-induced activation of 𝛼v𝛽
3
integrin need to be
elucidated. Jefferson and Alpers speculated that activation of
𝛼v𝛽
3
signaling by suPARmight require additional modifying
factors such as loss of podocyte protective factors or an
underlying permissive genetic background [77].
Recently, Yoo et al. [78] reported that SMPDL-3b is an
important regulator of suPAR-induced activation of 𝛼v𝛽
3
integrin signaling in podocytes. SMPDL-3b interferes with
binding of suPAR/uPAR and 𝛼v𝛽
3
integrin, attenuating 𝛼v𝛽
3
integrin activation. They showed that SMPDL-3b expression
is decreased in glomeruli of patients with recurrent FSGS and
FSGS sera-treated podocytes exhibited decreased SMPDL-3b
expression [78]. Therefore, high suPAR levels could increase
podocytic 𝛼v𝛽
3
integrin activation in FSGS patients with
nephrotic syndrome, while intact SMPDL-3b expression in
podocytes of normal subjects might offset 𝛼v𝛽
3
integrin
activation by inflammation-driven high suPAR.Notably, they
demonstrated that high suPAR in the presence of increased
podocyte SMPDL-3b levels in diabetic nephropathy did
not activate 𝛼v𝛽
3
integrin but led to RhoA activation and
podocyte apoptosis, indicating different effector pathways in
suPAR signaling [78].
We should also note that FSGS sera-treated podocytes
exhibited decreased SMPDL-3b expression but suPAR itself
did not modulate SMPDL-3b expression levels [78]. There-
fore, in our opinion, other unknown factors in FSGS might
reduce the SMPDL-3b expression in injured podocytes,
increasing the effect of suPAR on podocytes, and this has to
be clarified (Figure 1).
In summary, the role of suPAR in activating 𝛽
3
integrin in
podocytes has not been repeated in other groups and further
validation is necessary.
9. Areas of Uncertainty concerning the Sources
of suPAR
As mentioned above, various suPAR fragments exist with
different characteristics and whether or not the “true”
circulatory factor is a cleaved suPAR isoform remains
obscure. Wei et al. found a predominant suPAR fragment at
∼22 kDa [9].The importance of different suPAR domains was
highlighted by the finding that suPAR administration inmice
producing suPAR DI and DII domains induced albuminuria
[9]. Trachtman et al. considered that it is likely that all forms
of suPAR can bind to𝛼v𝛽
3
integrin, but subsequent activation
might vary depending on the specific form of suPAR [79].
Maas et al. speculated that vitronectin-binding capacity of
suPAR fragments might determine the activity as a FSGS
factor [75]. In addition, it should be considered that a glycosy-
lation status of suPAR may be causative of inducing protein-
uria in primary FSGS [80]. Because the currently available
ELISA kits can detect full-length glycosylated suPAR only
[80], characterization of the different isoforms and their
biologic activity is clearly warranted and should be addressed
by further studies, using novel kits. In addition, the levels of
different isoforms in active FSGS should be clearly clarified, as
the original clinical studies are difficult to reconcile if it is only
a specific isoform that is biologically active.
In summary, isoforms and glycosylation status of suPAR
should be considered and detection kits should be developed
in the future.
10. Areas of Uncertainty concerning suPAR
Serum Determinants
The time of specimen collection may influence suPAR levels
[81]. However, no differences between serum and plasma
suPAR levels were observed when samples were kept at room
temperature for a few hours, but suPAR levels increased after
an observation time of 72 hours. Repeated freeze and thaw
cycles had no influence on suPAR levels [82]. Therefore,
uniform specimen collection and only short-term storage at
room temperature should be targeted.
The relevance of demographics in the interpretation of
serum suPAR has to be highlighted. In healthy adults, mean
suPAR concentrations of approximately 2,000–4,000 pg/mL
have been reported [52]. Although there have only been
few studies on potential factors influencing suPAR levels in
the normal population, higher suPAR levels were found in
women, smokers, older subjects, and Africans (compared to
Caucasians) [52, 83]. Therefore, there is a strong need to
include these confounding factors in future studies investi-
gating the role of suPAR in FSGS.
Markers of systemic inflammation (i.e., C-reactive pro-
tein (CRP) or erythrocyte sedimentation rate (ESR)) should
be determined as well, since inflammation per se can affect
suPAR levels [16, 18, 52, 76]. A positive correlation between
suPAR and either CRP or ESR levels was shown in patients
with rheumatoid arthritis [76]. No correlation has been
reported between CRP and suPAR levels in FSGS so far [10,
13, 17]. However, there were correlations between suPAR and
high sensitivity CRP (hsCRP) levels or log CRP [16, 18].There
remains uncertainty towards the value of CRP as inflamma-
torymarker in nephrotic disease, but the use of hsCRPmay be
a more appropriate measure to correlate with suPAR [18] and
might be used in further studies.
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In most studies, eGFR is one of the strongest determi-
nants of suPAR concentration [14–24], but these findings
could not be confirmed in two studies [9, 13]. Accumulation
of suPAR in patients at lowGFRmayobfuscate FSGS-induced
suPAR accumulation [84]. Information about clearance, pro-
duction, and release of suPAR in patients with preserved or
impaired kidney function is lacking. Although several factors
such as inflammatory cytokines are increased in chronic
kidney disease (CKD) [85–87], we still do not know whether
these changes may lead to increased suPAR levels or not. In
one study, hemodialysis patients had very high suPAR levels.
Themedian suPAR in these patients was 12.3 ng/mL (controls
3.2 ng/mL, suPARnostic assay), which makes this group of
patients quite unique with regard to the extremely high
suPAR level [88].
In summary, suPAR serum determinants (collection time
of blood, ethnic differences, systemic inflammation, eGFR,
andmetabolism of suPAR) should be considered in interpret-
ing the results.
11. Areas of Uncertainty concerning
suPAR in FSGS
Most studies did not correlate suPAR levels with the different
histopathological variants of primary FSGS. Others reported
no differences among FSGS subtypes [11, 13, 89]. However,
Huang et al. found that suPAR levels were higher in tip-lesion
FSGS, followed by not otherwise specified and cellular variant
[12], whereas urinary suPAR levels were highest in patients
with the cellular variant [67]. They found no differences in
suPAR levels between primary and secondary FSGS [12],
but Segarra et al. found an association of suPAR levels with
the diagnosis of primary FSGS after adjusting for age, renal
function, and presence of nephrotic syndrome [89]. We
propose thatmultiple cohorts should be reanalyzed according
to the Columbia classification of primary FSGS to highlight
potential differences between the variants and this should be
considered in future studies as well.
Circulating factors such as suPAR have their most sig-
nificant role in patients at risk of recurrent FSGS after
KT. However, most studies did not measure suPAR levels
in recurrent versus nonrecurrent FSGS [11–24]. Another
limitation of research may be misclassification of FSGS cases,
since distinction between primary and secondary FSGS may
not be feasible in all patients. Wei et al. reported that FSGS
patients with an NPHS2 mutation had higher suPAR levels
than those without [10], butMaas et al. questioned this result,
because it is in contrast with the observation that recurrences
of FSGS occur most frequently in patients with nongenetic,
primary FSGS [75]. Jungraithmayr et al. reported that none of
the 11 patients with homozygous or compound heterozygous
NPHS2 mutations developed recurrent FSGS after KT com-
pared with 45% of patients without mutations [90]. There-
fore, higher suPAR levels in FSGS patients with an NPHS2
mutation might not influence the risk of recurrence after KT.
The incidence of NPHS2 mutations seems to be very rare in
Asian countries [91] and therefore suPAR studies from Asian
countries might rarely include FSGS patients with podocin
mutations. Early studies suggested that a few patients with
NPHS2 “mutations” do develop FSGS recurrence after KT
[92, 93], but subsequent information suggests that these may
not be true disease causing variants.
In summary, the role of suPAR should be interpreted in
the context with recurrent FSGS after KT, which is considered
to be circulating factor-mediated.
12. Areas of Uncertainty concerning
Immunosuppression and suPAR Levels
The use of immunosuppressive drugs (the kinds, the cumu-
lative dose, and the duration of immunosuppressants) at
the time of suPAR measurements should be considered.
Although most studies did not describe this crucial param-
eter, suPAR in the European PodoNet cohort comprising
steroid-resistant children and adolescents revealed lower
levels in the MMF-treated group, while no difference was
observed in patients with or without calcineurin inhibitor
treatment [10].Wada et al. showed that suPAR levels were sig-
nificantly lower in FSGS patients with normal renal function
who were treated with steroids or immunosuppressants than
in thosewithout, but the use of steroids/immunosuppressants
was not predictive of suPAR levels in those with glomerular
diseases [17]. Sinha et al. reported that serum suPAR levels
did not correlate with the duration of immunosuppressive
therapy [18]. A recent study showed that serum suPAR levels
decreased after MMF therapy, while they increased after
cyclosporine treatment in children withMCD and frequently
relapsing steroid-sensitive nephrotic syndrome with normal
renal function, suggesting that immunosuppressants per se
might have diverse effects on suPAR levels [94].
The immunologic nature of suPAR has to be considered,
because it may be influenced secondarily by immune acti-
vation. There might be an influence of cytokines such as
TNF-𝛼 and interleukin-2 (IL-2) on suPAR [95–97]. Although
not tested in FSGS, suPAR correlated with leukocyte count
and TNF-𝛼 [95] and several suPAR isoforms with soluble
TNF receptor-II in HIV-infected patients [96]. TNF-𝛼 was
supposed to be critical for uPAR expression on platelets [98].
Park et al. recently speculated that IL-2might be an important
cytokine for the formation of suPAR from T cells and natural
killer cells in FSGS [97].
Recently, Delville et al. [99] screened about 9000 antigens
in pretransplant sera of FSGS and pretransplant elevation of
anti-CD40 antibody (Ab) alone had the best correlation (78%
accuracy)with recurrent FSGS risk afterKT among sevenAbs
(CD40, PTPRO, CGB5, FAS, P2RY11, SNRPB2, and APOL2).
Anti-CD40 Abs purified from the sera of recurrent FSGS
patients were particularly pathogenic in human podocyte
cultures and injection of anti-CD40/rFSGS Ab enhanced
suPAR-mediated proteinuria in wild-type mice, but no sen-
sitizing effect was noted inmice deficient in CD40 or in wild-
type mice that received blocking Ab to CD40, supporting the
fact that suPAR might be formed by immunologically medi-
ated mechanisms in FSGS [99]. Therefore, further investiga-
tions are necessary to elucidate the role of various immuno-
logical molecules on podocytes, mice models of FSGS, and
patients with FSGS.
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More recently, recurrent FSGS after KT was successfully
treated with immunosuppressive treatments with high-dose
methylprednisolone and cyclosporine [100], potentially sup-
pressing TNF-𝛼 and IL-2. A TNF-𝛼 driven pathway in pri-
mary FSGS has also been supported by findings of Bitzan et
al. who reported a patient with recurrent and plasmapheresis-
resistant FSGSwith sustained partial remission of proteinuria
after initiation of anti-TNF-𝛼 therapy despite discontinuation
of plasmapheresis [101].Moreover, they showed that activated
podocyte 𝛽
3
integrin by plasma from patients with FSGS
recurrence could be reversed by blocking TNF-𝛼 in vitro
(Figure 1) [101].
Therefore, in our opinion, increased circulating factors
such as suPAR might reflect a secondary effect of immune
activation in FSGS. Treatment suppressing cytokines such as
TNF-𝛼 and IL-2 could induce remission possibly due to a
decrease of the circulating factors. It was speculated that a
cytokine such as TNF-𝛼might have direct deleterious effects
on podocytes in vivo [102] and this effect could be thera-
peutically targeted. However, the question remains whether
TNF-𝛼 is the specific elusive “factor” or just one out of several
factors affecting the glomerular filtration barrier or modu-
lating the immune response [102]. We think that glomerular
diseases like FSGS may develop when suPAR interacts with
other factors that injure podocytes in a proposed multiple
hit process. However, the precise effects of TNF-𝛼 or IL-2 on
podocytes have not been elucidated leaving the opportunity
that an inflammatory signal rather than suPAR is causing
FSGS-type lesions. We encourage consideration of additive
or synergic effects of several influences (circulatory factors,
genetic susceptibility, and local immunologic changes) on the
glomerular filtration barrier of which suPARmay be one such
influence ormay be pathologically altered by other cytokines.
In summary, suPAR may be an immunologically medi-
ated molecule and immunosuppression can suppress the
suPAR levels.
13. Conclusions and Future Perspectives
Circulating factors have been implicated in the pathogenesis
of recurrent FSGS after KT [7, 8] and suPAR has been
suggested as a potential candidate. Circulating suPAR could
activate 𝛽
3
integrin in a similar manner to membrane-bound
uPAR in podocytes, but further validations are necessary to
elucidate how much activation of 𝛽
3
integrin is relevant to
cause foot process effacement. suPAR could induce protein-
uria in vulnerable mice models [9], but administration of
suPAR to wild-type mice did not induce proteinuria [23, 68].
There might be a pivotal role of additional hits, such as
increased TNF-𝛼 and IL-2 or decreased SMPDL-3b expres-
sion in podocytes in the development of proteinuria [78, 97,
101]. In the clinical setting, recurrent nephrotic range pro-
teinuria in patients with nongenetic disease can be abrogated
by intensive immunosuppression possibly due to repression
of circulating factor formation, stabilization of the actin
cytoskeleton (e.g., cyclosporine), or prevention of SMPDL-3b
downregulation (e.g., rituximab) [62, 100, 103–106].
The conflicting results on suPAR levels between FSGS and
other glomerular diseases or controls may be attributable to
the heterogeneous nature of FSGS and various confounding
factors as stated above. As stated above, clinical studies should
be designed taking into account important covariates, for
example, the GFR. Future studies should also be designed
to formally evaluate the sensitivity, specificity, and predictive
value of suPAR.
We summarized the different results on various suPAR
studies in FSGS in Tables 1 and 2 and showed an integrative
model for the pathogenesis of circulating factor-mediated
FSGS in Figure 1. In our opinion, the data on the nature
and biological effect of specific suPAR molecular fragments
are incomplete so far. A single suPAR value is of no use as
clinical biomarker and suPAR itself may not be sufficient to
induce FSGS lesions. However, the downstream biological
effects via 𝛼v𝛽
3
integrin may still be valid and suPAR might
activate 𝛼v𝛽
3
integrin under other coexisting conditions such
as reduced SMPDL-3b expression by other serum factors of
FSGS or a costimulatory effect with TNF-𝛼.
We recommend and encourage further investigations in
this field to elucidate the role of various immunological
molecules on podocytes, mice models of FSGS, and patients
with FSGS. We suggest multicenter collaborative studies to
clarify the controversies related to suPAR as circulatory factor
in FSGS. We believe that understanding the immunology in
this field may facilitate unraveling pathogenic mechanisms
leading to FSGS.
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